Analytics unit of Wolters Kluwer to get new CEO

Share this article:
Spiers: left Wolters Kluwer in April
Spiers: left Wolters Kluwer in April
Wolters Kluwer Pharma Solutions will get a new CEO following the retirement of the pharmacy data and analytics firm's former head honcho, Mark Spiers, in April.

As interim CEO, the company named Robert Becker, who currently heads up sister company Wolters Kluwer Health. Becker will run both units until a permanent replacement for Spiers is found, said a source.

Becker has been CEO of Wolters Kluwer's Health division since 2008, after a five-year stint with the parent company that included running a unit of the Dutch conglomerate's Tax, Accounting & Legal division. Before that he was CEO of Jupiter-MediaMetrix.

Spiers is joining the board of directors of Qforma, which provides advanced analytics and predictive modeling technologies for the health sciences industry, Qforma said in an announcement.

Headquartered in Bridgewater, NJ, the Pharma Solutions unit includes pharmacy market data, healthcare analytics and marketing/publishing groups, as well as inThought Research, which offers pipeline analysis. The unit was separated from Wolters Kluwer Health in 2010.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...